13 Company uses a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO Patrik Jeanmonod - CFO Conference Call Participants David Westenberg - Piper Sandler Steven Mah - TD Cowen Matthew Sykes - Goldman Sachs Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Welcome to the Cytek Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's confer ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO Patrik Jeanmonod - CFO Conference Call Participants Steven Mah - TD Cowen David Westenberg - Piper Sandler Operator Good day, and thank you for standing by. Welcome to the Cytek Biosciences Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conferen ...

The customer relationships intangible asset represents the fair value of the underlying relationships with Luminex's FCI customers. The tradename intangible asset represents the fair value of brand and name recognition associated with the marketing of the acquired Luminex FCI product lines. The FCI developed technology intangible asset represents the fair value of access to certain imaging and microcapillary technologies. The fair value of the customer relationships intangible asset was determined based on ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Paul Goodson - Head Investor Relations Wenbin Jiang - Chief Executive Officer Patrik Jeanmonod - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Stephanie Yan - TD Cowen Operator Good afternoon, and thank you for standing by. Welcome to the Cytek Biosciences First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 CYTEK BIOSCIENCES, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-2547526 (State or other jurisdi ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 and Full Year 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Paul Goodson – Investor Relations Wenbin Jiang – Chief Executive Officer Patrik Jeanmonod – Chief Financial Officer Conference Call Participants David Westenberg – Piper Sandler Operator Good day, and thank you for standing by. Welcome to the Cytek’s Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference ...

If we are unable to successfully expand our commercial operations, including hiring additional qualified sales representatives, technical applications specialists and customer support staf , our business may be adversely af ected. Our future sales will depend, in large part, on our ability to develop and substantially expand our sales infrastructure, particularly as we enter into new markets, rollout new solutions and applications and manage inbound interest from new customers. We distribute our products th ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Paul Goodson - Head, IR Wenbin Jiang - President, CEO and Chairman Patrik Jeanmonod - CFO Conference Call Participants Tejas Savant - Morgan Stanley Matthew Sykes - Goldman Sachs David Westenberg - Piper Sandler Operator Welcome to Cytek's Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ...